Monument Mining Subsidiary Faces Tuckanarra Lawsuit Over Joint Venture Management Dispute
Bitget2026/10/20 16:36- Tuckanarra Resources initiated proceedings in Western Australia's Supreme Court against Monument Mining's wholly owned subsidiary, Monument Murchison.
- The injunction application seeks to block an October 21, 2026, joint venture committee meeting to appoint a replacement manager.
- Monument Murchison's August 25, 2026, breach notice concerns Tuckanarra's third-party toll milling agreement for the Tuckanarra Gold Project.
- The subsidiary maintains the breach remained unresolved, ending Tuckanarra's management role effective September 25, 2026; Tuckanarra disputes that position.
- Both parties agreed to interim arrangements and an expedited dispute timetable; court orders remain subject to determination.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Terranor Group schedules Q3 results presentation
WTI crude oil futures prices fall by more than 1%
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
Crypto prices
More
